Polyrotaxane Delivery Systems for NPC Cholesterol Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic agents and imaging contrast agents face challenges due to high clearance and toxicity, particularly for conditions like Niemann-Pick type C disease and angiographic enhancement, where current agents have short persistence and acute toxicity issues.
Innovation Solution
Development of polyrotaxanes, which are supramolecular materials composed of a macrocyclic host molecule threaded onto a polymer chain with endcapping groups, providing a platform for sustained release of therapeutic agents like hydroxypropyl-β-cyclodextrin and imaging contrast agents, enhancing pharmacokinetics and biodistribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If β-cyclodextrin and its derivatives are used as therapeutic agents, then cholesterol clearance is improved, but persistence in bloodstream is brief and high clearance occurs
Solution Approach 1:
The patent combines β-cyclodextrin with biocompatible polymers (such as polyethylene glycol or polylactic acid) to create composite nanoparticle systems. This composite structure allows the therapeutic agent to maintain its cholesterol-clearing capability while the polymer component provides extended circulation time by reducing renal clearance and protecting against premature degradation, thereby resolving the contradiction between high productivity and brief duration of action.
Solution Approach 2:
The patent embeds β-cyclodextrin molecules within nanoparticle carriers, creating a nested structure where the therapeutic agent is contained within a protective matrix. This nesting approach allows the small cyclodextrin molecules to retain their therapeutic function while the larger nanoparticle structure prevents rapid renal filtration, thus extending bloodstream persistence without compromising cholesterol clearance efficiency.
2Productivity
If high dosages of β-cyclodextrin are administered, then cholesterol clearance is improved, but acute toxicity increases
Solution Approach 1:
The patent divides the therapeutic dose into multiple smaller units by incorporating β-cyclodextrin into nanoparticle formulations. This segmentation allows the total therapeutic dose to be distributed across numerous particles, each delivering a controlled amount of the active agent. The result is improved cholesterol clearance through sustained release while reducing acute toxicity by avoiding high concentrated doses, as the nanoparticles enable gradual therapeutic delivery.
Solution Approach 2:
The patent introduces biocompatible polymer materials as intermediaries between the therapeutic agent and the biological system. These intermediary materials (such as PEG coatings or biodegradable polymer matrices) mediate the delivery of β-cyclodextrin, reducing direct toxicity effects while maintaining therapeutic efficacy. The intermediary layer protects surrounding tissues from the harsh effects of high dosages while still allowing the cyclodextrin to perform its cholesterol-clearing function.
3Measurement precision
If clinically used contrast agents are administered, then paramagnetism and relaxation enhancement are improved, but clearance from body is rapid
Solution Approach 1:
The patent merges imaging contrast agents (such as gadolinium-based paramagnetic compounds) with therapeutic nanoparticle carriers to create multifunctional agents. This merging allows the contrast agent to maintain its excellent paramagnetic properties and relaxation enhancement capabilities for high-quality imaging, while the nanoparticle carrier provides extended circulation time. The combined system enables both superior imaging contrast and prolonged persistence in the body, resolving the contradiction between measurement precision and duration of action.
4Duration of action of moving object
If nanoparticulate platforms are used as carriers, then persistence is improved, but toxicity may increase
Solution Approach 1:
The patent carefully controls key parameters of the nanoparticle system, including size (typically 10-100 nm), surface charge (near-neutral or slightly negative), and composition (biocompatible and biodegradable materials). By optimizing these parameters, the nanoparticles achieve extended circulation time through reduced renal clearance and avoided macrophage uptake, while simultaneously minimizing toxicity through biocompatible material selection and controlled degradation profiles, thus resolving the contradiction between persistence and toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polyrotaxane system allows for long-circulating, biocompatible delivery of therapeutic agents, effectively increasing cholesterol clearance in Niemann-Pick type C disease and providing improved contrast and prolonged imaging capabilities with reduced toxicity.
Implementation Method 1
A polyrotaxane is a macrocylic host molecule or molecules that is/are 'threaded' onto a polymer chain of compatible dimensions via host-guest hydrophobic interactions
Data Source
AI summary
Various embodiments of the present invention are directed to polyrotaxanes comprising a poloxamer core and at least one cyclodextrin and methods for treating Niemann-Pick type C (NPC) and imaging (e.g., MRI) using the polyrotaxanes various embodiments of the present invention.